Altre lingue Annexin Pharmaceuticals AB

Azioni

ANNX

SE0009664154

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 16:54:42 26/04/2024			Variaz. 5gg	Var. 1 gen.
0,297 ^SEK	+2,41%		+10,00%	+14,23%

12/04	Annexin Pharmaceuticals AB (publ) riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
09/02	Annexin Pharmaceuticals AB (publ) riporta i risultati degli utili per il quarto trimestre e l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Last patient treated in Annexin’s RVO study - promising signals of effect and no safety concerns	25/04
BioStock: Annexin towards completion of phase II study and share issue	18/04
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	12/04
Annexin resolves on a rights issue of SEK 45.1 million guaranteed to 90 percent, subject to approval by the 2024 Annual General Meeting, which has been decided to be brought forward	28/03
BioStock: Strong start for Annexin in 2024	14/02
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	09/02
Update on Annexin´s RVO study confirms promising signals of effect	08/02
Annexin Pharmaceuticals AB Provides Update on RVO Study Confirms Promising Signals of Effect	08/02
Annexin presents at Redeye’s Fight Cancer event on January 24	18/01
Annexin announces outcome of the rights issue and resolves on directed issues to guarantors and lenders	18/12
The subscription period in Annexin Pharmaceuticals’ rights issue begins today	30/11
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue	28/11
First patients treated with higher dose without adverse events in Annexin's RVO study	23/11
Annexin granted additional patent protection in the US	14/11
Annexin Pharmaceuticals AB Announces Additional Patent Protection in the US	14/11
First patient treated in the second dose group in Annexin's RVO study	25/10/23
First patient treated in the second dose group in Annexin's RVO study	25/10/23
Annexin Pharmaceuticals AB Announces First Patient Treated in the Second Dose Group in RVO Study	25/10/23
Annexin resolves a SEK 35.6 million fully guaranteed rights issue, subject to approval of an Extraordinary General Meeting	24/10/23
BioStock: Annexin's CSO on progress in cancer initiative	18/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Annexin Pharmaceuticals AB

Azioni

ANNX

SE0009664154

Altre lingue

Filtri